Sugi Predict

Sugi Predict / Compounds / SCHEMBL16397243

SCHEMBL16397243

SCHEMBL16397243

CN(C)C(c1cc(COc2ccccc2CC(=O)O)cc(-c2cccc(CN)c2)c1)C(F)(F)F

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 18/20 0.67
▸ F11 P03951 11/20 0.67
▸ TPSB2 P20231 9/20 0.67
▸ PLAU P00749 3/20 0.67
▸ KLKB1 P03952 3/20 0.67
▸ PLG P00747 2/20 0.67
▸ F7 P08709 2/20 0.67
▸ F2 P00734 1/20 0.50
▸ F9 P00740 1/20 0.50
▸ F10 P00742 1/20 0.50
▸ PLAT P00750 1/20 0.50
▸ PTGS1 P23219 1/20 0.50
▸ SLC18A2 Q05940 1/20 0.50
▸ PDE4D Q08499 1/20 0.50
▸ KCNH2 Q12809 1/20 0.50
▸ PTGER1 P34995 1/20 0.45
▸ PTGER4 P35408 1/20 0.45
▸ PTGER3 P43115 1/20 0.45
▸ PTGER2 P43116 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16397129 0.88 CFD (0.70) CFDF11TPSB2PLAUKLKB1
SCHEMBL16397051 0.87 CFD (0.66) CFDF11TPSB2PLAUKLKB1
SCHEMBL16396661 0.85 CFD (0.74) CFDF11TPSB2PLAUKLKB1
SCHEMBL16402326 0.85 CFD (0.66) CFDF11TPSB2PLAUKLKB1
SCHEMBL16410512 0.83 CFD (0.91) CFDF11TPSB2PLAUKLKB1
SCHEMBL16396439 0.83 CFD (0.62) CFDF11TPSB2PLAUKLKB1
SCHEMBL16410405 0.82 CFD (0.67) CFDF11TPSB2PLAUKLKB1
SCHEMBL16396813 0.82 CFD (0.47) CFDF11TPSB2PLAUKLKB1
SCHEMBL16410407 0.81 CFD (0.66) CFDF11TPSB2PLAUKLKB1
SCHEMBL16397328 0.81 CFD (0.66) CFDF11TPSB2PLAUKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 — — EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB CFD 1/4885F11 17/4885TPSB2 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.